The ARlncRNA ACTA2-AS1 suppresses cisplatin resistance in NSCLC via engaging enhancer of Zeste 2 (EZH2) to the TSC2 gene promoter and decreasing tuberous sclerosis complex-2 (TSC2) expression.45 The gene discussed is TSC2; the disease is non-small cell lung carcinoma.